Akero Therapeutics
$26.41
24
+$0.06+0.23% Friday 20:00
Statistics
Day High
26.96
Day Low
25.68
52W High
53.77
52W Low
11.25
Volume
437,087
Avg. Volume
710,751
Mkt Cap
1.89B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13NovExpected
Expected EPS
-0.85
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AKRO. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap5.37B
Viking Therapeutics
VKTX
Mkt Cap7.1B
Galmed Pharmaceuticals
GLMD
Mkt Cap2.18M
Gilead Sciences
GILD
Mkt Cap98.35B
Agios Pharmaceuticals
AGIO
Mkt Cap2.61B
FibroGen
FGEN
Mkt Cap36.71M
Abbvie
ABBV
Mkt Cap346.75B
Analyst Ratings
43.5$Average Price Target
The highest estimate is $56.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%
About
Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Show more...
CEO
Employees
61
Country
US
ISIN
US00973Y1082